Literature DB >> 8127665

Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.

C J Pachuk1, K Yoon, K Moelling, L R Coney.   

Abstract

Conventionally designed ribozymes may be unable to cleave RNA at sites which are inaccessible due to secondary structure. In addition, it may also be difficult to specifically target a conventionally designed ribozyme to some chimeric RNA molecules. Novel approaches for ribozyme targeting were developed by using the L6 bcr-abl fusion RNA as a model. Using one approach, we successfully directed ribozyme nucleation to a site on the bcr-abl RNA that is distant from the GUA cleavage site. These ribozymes bound to the L6 substrate RNA via an anchor sequence that was complementary to bcr sequences. The anchor was necessary for efficient cleavage as the anchor minus ribozyme, a conventionally designed ribozyme, was inefficient at catalyzing cleavage at this same site. The effect of anchor sequences on catalytic rates was determined for two of these ribozymes. Ribozymes generated by a second approach were designed to cleave at a CUU site in proximity to the bcr-abl junction. Both approaches have led to the development of a series of ribozymes specific for both the L6 and K28 bcr-abl chimeric RNAs, but not normal abl or bcr RNAs. The specificity of the ribozyme correlated in part with the ability of the ribozyme to bind substrate as demonstrated by gel shift analyses. Secondary structure predictions for the RNA substrate support the experimental results and may prove useful as a theoretical basis for the design of ribozymes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8127665      PMCID: PMC523580          DOI: 10.1093/nar/22.3.301

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  10 in total

1.  Substrate sequence effects on "hammerhead" RNA catalytic efficiency.

Authors:  M J Fedor; O C Uhlenbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

2.  Ribozyme-mediated cleavage of an HIV-1 gag RNA: the effects of nontargeted sequences and secondary structure on ribozyme cleavage activity.

Authors:  N R Taylor; J J Rossi
Journal:  Antisense Res Dev       Date:  1991

3.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

4.  Simple RNA enzymes with new and highly specific endoribonuclease activities.

Authors:  J Haseloff; W L Gerlach
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

5.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

6.  Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.

Authors:  E Shtivelman; B Lifshitz; R P Gale; B A Roe; E Canaani
Journal:  Cell       Date:  1986-10-24       Impact factor: 41.582

7.  Structural organization of the bcr gene and its role in the Ph' translocation.

Authors:  N Heisterkamp; K Stam; J Groffen; A de Klein; G Grosveld
Journal:  Nature       Date:  1985 Jun 27-Jul 3       Impact factor: 49.962

8.  Kinetics of intermolecular cleavage by hammerhead ribozymes.

Authors:  M J Fedor; O C Uhlenbeck
Journal:  Biochemistry       Date:  1992-12-08       Impact factor: 3.162

9.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

10.  Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.

Authors:  N Heisterkamp; J R Stephenson; J Groffen; P F Hansen; A de Klein; C R Bartram; G Grosveld
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

  10 in total
  10 in total

1.  Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.

Authors:  T Kuwabara; M Warashina; T Tanabe; K Tani; S Asano; K Taira
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

2.  Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells.

Authors:  M Homann; M Tabler; S Tzortzakaki; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

Review 3.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 4.  Antisense approaches to the gene therapy of cancer--'Recnac'.

Authors:  I Gibson
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

5.  The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells.

Authors:  R Hormes; M Homann; I Oelze; P Marschall; M Tabler; F Eckstein; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1997-02-15       Impact factor: 16.971

6.  Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle.

Authors:  J L Gu; J Nadler; J Rossi
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

7.  Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes.

Authors:  M Zoumadakis; M Tabler
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

8.  A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.

Authors:  M Tabler; M Homann; S Tzortzakaki; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

Review 9.  Ribozyme therapy: RNA enzymes to the rescue.

Authors:  Antony M Jose
Journal:  Yale J Biol Med       Date:  2002 Jul-Aug

10.  Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8.

Authors:  H Matsushita; M Kizaki; H Kobayashi; A Muto; Y Ikeda
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.